Medpace Holdings Inc (MEDP)
389.32
-8.24
(-2.07%)
USD |
NASDAQ |
Apr 25, 16:00
389.32
0.00 (0.00%)
After-Hours: 20:00
Medpace Holdings Gross Profit Margin (Quarterly): 30.36% for March 31, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 30.36% |
| December 31, 2023 | 27.45% |
| September 30, 2023 | 27.04% |
| June 30, 2023 | 26.97% |
| March 31, 2023 | 29.99% |
| December 31, 2022 | 29.37% |
| September 30, 2022 | 31.02% |
| June 30, 2022 | 28.19% |
| March 31, 2022 | 29.82% |
| December 31, 2021 | 28.52% |
| September 30, 2021 | 29.47% |
| June 30, 2021 | 26.82% |
| March 31, 2021 | 30.17% |
| December 31, 2020 | 31.91% |
| September 30, 2020 | 32.19% |
| June 30, 2020 | 27.63% |
| March 31, 2020 | 28.19% |
| December 31, 2019 | 27.27% |
| September 30, 2019 | 29.67% |
| Date | Value |
|---|---|
| June 30, 2019 | 29.79% |
| March 31, 2019 | 27.42% |
| December 31, 2018 | 31.74% |
| September 30, 2018 | 30.83% |
| June 30, 2018 | 31.43% |
| March 31, 2018 | 28.10% |
| December 31, 2017 | 38.94% |
| September 30, 2017 | 41.16% |
| June 30, 2017 | 40.10% |
| March 31, 2017 | 40.03% |
| December 31, 2016 | 40.93% |
| September 30, 2016 | 40.44% |
| June 30, 2016 | 40.96% |
| March 31, 2016 | 40.99% |
| December 31, 2015 | 43.17% |
| September 30, 2015 | 43.28% |
| June 30, 2015 | 43.43% |
| March 31, 2015 | 44.45% |
| March 31, 2014 | 40.41% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
26.82%
Minimum
Jun 2021
32.19%
Maximum
Sep 2020
29.09%
Average
29.42%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Charles River Laboratories International Inc | 35.92% |
| Avid Bioservices Inc | -18.37% |
| Iovance Biotherapeutics Inc | -805.6% |
| Renovaro Inc | -- |
| Candel Therapeutics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 64.05% |
| Return on Assets | 20.18% |
| Return on Invested Capital | 59.87% |
| Profit Margin (Quarterly) | 20.07% |
| Operating Margin (Quarterly) | 20.36% |
| Return on Net Operating Assets | 25.24% |